Tazemetostat is an oral, first-in-class, EZH2 inhibitor discovered by Epizyme and being developed for a range of cancers and treatment settings. This NDA submission follows a recently conducted
As part of strategic collaboration and licence agreement, the partnership will offer first broadly-available imaging biomarker research tool to pharmaceutical companies and major academic centers carrying out research
In this multicenter, randomized, double-blind phase III QUARTZ study (ClinicalTrials.gov Identifier: NCT02892344), once-daily, low dose IND/MF (QMF149) 150/80 Mu g met the primary and key secondary endpoints (trough
Xeomin is claimed to be the first and only neurotoxin with this approved indication in the EU. It secured approval from the US Food and Drug Administration (FDA)
Revlimid plus rituximab is claimed to be the FDA-approved combination treatment regimen for patients with these indolent forms of non-Hodgkin’s lymphoma (NHL), which does not include chemotherapy. Celgene
“Our collaboration with Hansoh Pharma strengthens our ability to commercialize inebilizumab throughout the world,” commented Bing Yao, Ph.D., Viela’s Executive Chairman and Chief Executive Officer. “Their significant commercial,
Transgene confirms that the study’s primary endpoint (objective response rate – ORR) on a minimum of 35 evaluable patients will be reported in Q4 2019. The Phase 2
Neuraxpharm has entered into an exclusive licensing agreement with the probiotics company Bened Biomedical, under which Neuraxpharm secured exclusive rights to market its first probiotic lactobacillus plantarum PS128
The FDA has approved Piqray kinase inhibitor in combination with fulvestrant to treat postmenopausal women, and men with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-),
“Today’s approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” said Acting FDA Commissioner Ned Sharpless, M.D.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.